Smart Drug Strikes RNA Weak Point in Cancer Cells
- Researchers at the University of california, San Diego, have developed a molecule capable of selectively destroying a specific RNA molecule, TERRA, that fuels the growth of certain cancers.
- Sylvie Benhamou and colleagues Khaskia, and Dipak Dahatonde of the University of California, San Diego's Faculty of Medicine, focuses on TERRA (Telomeric Repeat-containing RNA).TERRA is an RNA molecule...
- Several cancers, including specific brain and bone tumors, exploit improperly functioning TERRA to promote uncontrolled growth and division.Cancer cells utilize TERRA to bypass normal cellular safeguards,allowing them to...
“`html
New ’Guided Missile’ Molecule Targets cancer-Promoting RNA, Offering Hope for Novel Therapies
Table of Contents
Researchers at the University of california, San Diego, have developed a molecule capable of selectively destroying a specific RNA molecule, TERRA, that fuels the growth of certain cancers. This breakthrough offers a new avenue for cancer treatment by targeting RNA directly, rather than solely focusing on proteins.
The Role of TERRA in Cancer Progress
The research, led by Dr. Sylvie Benhamou and colleagues Khaskia, and Dipak Dahatonde of the University of California, San Diego’s Faculty of Medicine, focuses on TERRA (Telomeric Repeat-containing RNA).TERRA is an RNA molecule crucial for maintaining the integrity of telomeres – protective caps at the ends of chromosomes that are vital for cell stability and healthy aging. When TERRA malfunctions, it can disrupt normal cell processes.
Several cancers, including specific brain and bone tumors, exploit improperly functioning TERRA to promote uncontrolled growth and division.Cancer cells utilize TERRA to bypass normal cellular safeguards,allowing them to proliferate relentlessly. Understanding this mechanism is key to developing targeted therapies.
Introducing RIBOTAC: A Targeted RNA Destroyer
“We’ve created a tool that acts like a guided missile for bad RNA,” explained Dr. Benhamou. “It can find TERRA inside cancer cells and make it disappear - without harming healthy parts of the cell.” This “guided missile” is a small molecule built using RIBOTAC (Ribonuclease-Targeting Chimera) technology.
RIBOTAC works by identifying a unique structural feature within TERRA called a G-quadruplex – a folded, four-stranded structure in the RNA. Once identified, the RIBOTAC molecule recruits a naturally occurring cellular enzyme, rnase L, to specifically break down the TERRA molecule. This process effectively silences the cancer-promoting RNA.
This marks the first presentation of a tool capable of destroying TERRA wiht such precision. Crucially, the molecule demonstrates selectivity, targeting TERRA without affecting other RNA molecules with similar characteristics. This specificity minimizes potential off-target effects and enhances safety.
Promising Results in Cancer Cell Lines
In laboratory experiments, the RIBOTAC molecule was tested on cancer cell lines, including HeLa cells (derived from cervical cancer) and U2OS cells (representing a especially aggressive form of bone cancer, osteosarcoma). The treatment successfully lowered TERRA levels within these cells, leading to a measurable slowing of cancer cell growth. The National Cancer Institute defines cancer as the uncontrolled growth of abnormal cells.
these initial findings suggest the potential for this approach to be effective against cancers that rely on TERRA for their survival and proliferation. further research is needed to confirm these results in more complex models and ultimately in human clinical trials.
Reshaping the Future of Cancer Therapies
this research represents a paradigm shift in cancer treatment,moving beyond the traditional focus on proteins to directly target RNA molecules. Most current drugs are designed to inhibit or activate proteins, but RNA plays a critical role in regulating protein production. Targeting RNA offers a new layer of control.
“This is a new way of thinking about medicine,” said Benhamou. “Instead of focusing only on proteins, we’re now learning how to target the RNA that controls them. That could open the door to treating diseases we once thought were impossible to reach.” This approach could be particularly valuable for cancers that have developed resistance to protein-targeting therapies.